Home > Haematology > EHA 2020 > Promising first-in-human trial of epcoritamab in B-NHL

Promising first-in-human trial of epcoritamab in B-NHL

Dr Martin Hutchings (Copenhagen University Hospital, Denmark) presented the findings of the dose-escalation phase 1-2 GEN3013 trial in B-cell non-Hodgkin lymphoma (B-NHL) in an e-poster [1]. Epcoritamab administered subcutaneously demonstrated a favourable safety profile, with initial data suggesting promising and durable responses.

The rationale behind this study stems from the fact that most B-NHL patients relapse or become refractory (R/R) to CD20-specific monoclonal antibodies, but CD3xCD20 bispecific antibodies have shown promising results and may ameliorate resistance. The current poster presented dose-escalation data from the ongoing trial testing epcoritamab, a novel, subcutaneously administered CD3xCD20 agent. The primary endpoints were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). A key secondary objective was to analyse initial anti-tumour efficacy...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on